

ANCOVA of Change from Baseline Glucose (mmol/L) at Week 24  
 LOCF  
 Efficacy Analysis Population

	Baseline		Week 24		Change from Baseline		
Treatment	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)	LS Mean (95% CI) <sup>a</sup>
Placebo	79	5.7 (2.23)	79	5.6 (1.65)	79	-0.0 (2.32)	0.07 (-0.26, 0.41)
Xanomeline Low Dose	79	5.4 (0.95)	79	5.4 (1.06)	79	-0.1 (1.02)	-0.11 (-0.44, 0.23)
Xanomeline High Dose	74	5.4 (1.37)	74	5.8 (2.21)	74	0.4 (1.65)	0.39 (0.04, 0.74)
Pairwise Comparison			Difference in LS Mean (95% CI) <sup>a</sup>				p-Value
Xanomeline Low Dose - Placebo			-0.18 (-0.65, 0.30)				0.467
Xanomeline High Dose - Placebo			0.32 (-0.17, 0.80)				0.200
<sup>a</sup> Based on an ANCOVA model after adjusting baseline value. LOCF approach is used to impute missing values. ANCOVA = Analysis of Covariance, LOCF = Last Observation Carried Forward CI = Confidence Interval, LS = Least Squares, SD = Standard Deviation							

Source: ADLBC dataset